Page last updated: 2024-11-08

dihydrobunolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dihydrobunolol: major metabolite of bunolol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162349
CHEBI ID29109
MeSH IDM0065344

Synonyms (13)

Synonym
38947-37-4
(+-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol
dihydrobunolol
CHEBI:29109
5-[rac-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-ol
(+/-)-5-[(tert-butylaminol)-2'-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol
C04875 ,
(+/-)-dihydrobunolol
(+/-)-5-[(tert-butylamino)-2'-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol
5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-ol
1-naphthalenol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-
5-(3-(tert-butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalen-1-ol
DTXSID80959789

Research Excerpts

Overview

Dihydrobunolol (DHB) is an ocular metabolite equipotent to levobunolOL.

ExcerptReferenceRelevance
"Dihydrobunolol (DHB) is an equipotent metabolite of levobunolol."( Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits.
Acheampong, AA; Breau, A; Lam, S; Luo, W; Shackleton, M; Tang-Liu, DD, 1995
)
1.01
"Dihydrobunolol is an ocular metabolite equipotent to levobunolol. "( Ocular metabolism of levobunolol.
Richman, JB; Shackleton, M; Tang-Liu, DD, 1988
)
1.72

Dosage Studied

ExcerptRelevanceReference
" The tpeak was 15 min after dosing and the Cmax was 4 micrograms/mL."( Disposition of levobunolol after an ophthalmic dose to rabbits.
Liu, S; Neff, J; Sandri, R; Tang-Liu, DD, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphtholsAny hydroxynaphthalene derivative that has a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's3 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.93 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]